Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients
2016 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 11, no 10, e0165027Article in journal (Refereed) Published
Objective: To investigate risk of premenopausal and postmenopausal breast cancer among Multiple Sclerosis (MS) patients, considering tumor stage.
Methods: The Swedish Patient Register identified 19,330 women with MS between 1968 and 2012, matched individually with a cohort of 193,458 without MS. Matching variables were year of birth, sex, region of residence and vital status at the time of diagnosis. The cancer register identified 471 and 5,753 breast cancer cases among the MS and non-MS cohorts, respectively. Cox proportional hazard models estimated hazard ratios (HR) and 95% confidence intervals (CI) for premenopausal and postmenopausal breast cancer.
Results: Overall risk of postmenopausal breast cancer was 13% higher among MS patients compared with women without MS (HR = 1.13, 95% CI 1.02-1.26). Stratified analyses showed that the risk was statistically significantly increased in women diagnosed between 1968 and 1980 and those who were diagnosed at age 65 or older age. We observed a non-statistically significant risk only for stage 0-1 postmenopausal breast cancer (HR = 1.17, 95% CI 0.93-1.48). MS was not associated with premenopausal breast cancer.
Conclusion: The modest increased risk of postmenopausal breast cancer in women with MS may be due to surveillance bias, where contact with health services for one disease increases the risk of a second diagnosis being recorded.
Place, publisher, year, edition, pages
San Francisco, USA: Public Library of Science , 2016. Vol. 11, no 10, e0165027
Cancer and Oncology
IdentifiersURN: urn:nbn:se:oru:diva-53361DOI: 10.1371/journal.pone.0165027ISI: 000389009200035PubMedID: 27776164ScopusID: 2-s2.0-84992393596OAI: oai:DiVA.org:oru-53361DiVA: diva2:1044194
Novartis Pharma AG
F. Hoffmann La Roche Ltd.
AsteraZeneca pharmaceutical company2016-11-022016-11-022017-01-03Bibliographically approved